John Edward A. Blair to Heart Failure
This is a "connection" page, showing publications John Edward A. Blair has written about Heart Failure.
Connection Strength
3.558
-
Left Ventricular Pressure Ratio Predicts In-Hospital Outcomes in Hospitalized Heart Failure With Reduced Ejection Fraction. J Invasive Cardiol. 2021 Jul; 33(7):E507-E515.
Score: 0.404
-
Coronary Microvascular Dysfunction and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. J Card Fail. 2019 10; 25(10):843-845.
Score: 0.357
-
Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2018 05 01; 314(5):H1033-H1042.
Score: 0.321
-
Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report. ESC Heart Fail. 2017 11; 4(4):645-648.
Score: 0.307
-
Heart Failure With Preserved Ejection Fraction: Have We Finally Found the Perfect Noninvasive Biomarker? Circ Cardiovasc Imaging. 2016 12; 9(12).
Score: 0.295
-
Heart failure in North America. Curr Cardiol Rev. 2013 May; 9(2):128-46.
Score: 0.230
-
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J. 2009 Jul; 30(13):1666-73.
Score: 0.175
-
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008 Nov 11; 52(20):1640-8.
Score: 0.169
-
Usefulness of hand-carried ultrasound to predict elevated left ventricular filling pressure. Am J Cardiol. 2009 Jan 15; 103(2):246-7.
Score: 0.169
-
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther. 2008 May-Jun; 15(3):231-40.
Score: 0.163
-
Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care. 2007; 9(4):207-13.
Score: 0.148
-
A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Fail. 2021 10; 8(5):3495-3503.
Score: 0.102
-
Aortic Pulsatility Index: A Novel Hemodynamic Variable for Evaluation of Decompensated Heart Failure. J Card Fail. 2021 10; 27(10):1045-1052.
Score: 0.101
-
Aortic pulsatility index predicts clinical outcomes in heart failure: a sub-analysis of the ESCAPE trial. ESC Heart Fail. 2021 04; 8(2):1522-1530.
Score: 0.099
-
Left Ventricular Assist Device Deactivation via Percutaneous Closure of the Outflow Graft. J Card Fail. 2016 Aug; 22(8):653-5.
Score: 0.071
-
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012 Jul; 13(7):415-22.
Score: 0.054
-
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010 May; 159(5):841-849.e1.
Score: 0.047
-
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010 May; 12(5):423-33.
Score: 0.046
-
Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. J Card Fail. 2010 Jan; 16(1):69-75.
Score: 0.045
-
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J. 2009 Sep; 158(3):437-43.
Score: 0.045
-
Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J. 2009 Jun; 157(6):1035-41.
Score: 0.044
-
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 2009 Dec; 14(4):277-87.
Score: 0.043
-
Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging. 2008 Sep; 1(5):595-601.
Score: 0.042
-
Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design. Heart Fail Rev. 2009 Jun; 14(2):101-12.
Score: 0.041
-
Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008 Jun 10; 51(23):2276-85.
Score: 0.041